Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Proteomic and metabolomic strategies to investigate HIV-associated neurocognitive disorders | Pendyala and Fox Genome Medicine 2010 2 22 http content 2 3 22 w Genome Medicine REVIEW L_ Proteomic and metabolomic strategies to investigate HIV-associated neurocognitive disorders Gurudutt Pendyala and Howard S Fox Abstract Diagnosing neurodegenerative diseases monitoring their progression and assessing responses to treatments will all be aided by the identification of molecular markers of different stages of pathology. Protein biomarkers for HIV-associated neurocognitive disorders that have been discovered using proteomics include complement C3 soluble superoxide dismutase and a prostaglandin synthase. Metabolomics has not yet been widely used for biomarker discovery but early work shows that it has great potential. Background Human immunodeficiency virus HIV is a lentivirus that targets CD4 cells in vivo including a subset of lymphocytes CD4 T cells and a broad range of mononuclear phagocytes including monocytes dendritic cells tissue macrophages and brain microglia. The destruction of CD4 T cells and immune dysfunction results in a progressive immunodeficiency called acquired immunodeficiency syndrome AIDS which in the absence of treatment leads to opportunistic infections and malignancies 1 . Although immune system disorders have been focused on the most HIV infection also has significant effects on the central nervous system CNS as the virus both infects and affects the brain 2 . The associated neuropsychopathology or CNS dysfunction then leads to a group of cognitive and behavioral changes now termed HIV-1-associated neurocognitive disorders HAND or neuroAIDS. NeuroAIDS encompasses a broad range of neurological abnormalities including asymptomatic neurocognitive impairment HIV-associated mild Correspondence hfox@ Department of Pharmacology and Experimental Neuroscience University of Nebraska Medical Center 985800 Nebraska Medical Center Omaha NE 68198 USA 2 BioMed Central 2010 BioMed Central Ltd cognitive motor disorder and
